WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

248.06 USD
+2.2 (+0.89%)
At close: Mar 9, 2026
248.06 USD
0 (0%)
After Hours: 3/9/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

WST gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. WST scores excellent points on both the profitability and health parts. This is a solid base for a good stock. While showing a medium growth rate, WST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. WST Profitability Analysis

1.1 Basic Checks

  • WST had positive earnings in the past year.
  • In the past year WST had a positive cash flow from operations.
  • In the past 5 years WST has always been profitable.
  • In the past 5 years WST always reported a positive cash flow from operatings.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • WST has a Return On Assets of 11.56%. This is amongst the best in the industry. WST outperforms 92.98% of its industry peers.
  • WST has a better Return On Equity (15.54%) than 89.47% of its industry peers.
  • WST has a better Return On Invested Capital (14.09%) than 92.98% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for WST is above the industry average of 11.85%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • The Profit Margin of WST (16.06%) is better than 84.21% of its industry peers.
  • WST's Profit Margin has been stable in the last couple of years.
  • WST's Operating Margin of 20.53% is amongst the best of the industry. WST outperforms 87.72% of its industry peers.
  • WST's Operating Margin has been stable in the last couple of years.
  • WST's Gross Margin of 35.91% is on the low side compared to the rest of the industry. WST is outperformed by 61.40% of its industry peers.
  • WST's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. WST Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • WST has less shares outstanding than it did 1 year ago.
  • WST has less shares outstanding than it did 5 years ago.
  • WST has a better debt/assets ratio than last year.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • WST has an Altman-Z score of 12.81. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.81, WST belongs to the top of the industry, outperforming 98.25% of the companies in the same industry.
  • WST has a debt to FCF ratio of 0.44. This is a very positive value and a sign of high solvency as it would only need 0.44 years to pay back of all of its debts.
  • WST has a Debt to FCF ratio of 0.44. This is amongst the best in the industry. WST outperforms 92.98% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that WST is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.06, WST is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 12.81
ROIC/WACC1.31
WACC10.78%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that WST has no problem at all paying its short term obligations.
  • WST has a Current ratio (3.02) which is comparable to the rest of the industry.
  • A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
  • The Quick ratio of WST (2.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. WST Growth Analysis

3.1 Past

  • WST shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.00%.
  • The Earnings Per Share has been growing by 8.94% on average over the past years. This is quite good.
  • WST shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.50% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.60% on average over the next years.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 34.03, which means the current valuation is very expensive for WST.
  • WST's Price/Earnings is on the same level as the industry average.
  • The average S&P500 Price/Earnings ratio is at 26.46. WST is valued slightly more expensive when compared to this.
  • With a Price/Forward Earnings ratio of 30.62, WST can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than the industry average as 61.40% of the companies are valued more expensively.
  • WST's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.65.
Industry RankSector Rank
PE 34.03
Fwd PE 30.62
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, WST is valued a bit cheaper than 68.42% of the companies in the same industry.
  • 63.16% of the companies in the same industry are more expensive than WST, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 38.1
EV/EBITDA 21.54
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • WST has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.05
PEG (5Y)3.8
EPS Next 2Y11.07%
EPS Next 3Y11.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. WST Dividend Analysis

5.1 Amount

  • WST has a yearly dividend return of 0.32%, which is pretty low.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.10. WST pays more dividend than 84.21% of the companies in the same industry.
  • With a Dividend Yield of 0.32, WST pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 12.40% of the earnings are spent on dividend by WST. This is a low number and sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (3/9/2026, 8:04:00 PM)

After market: 248.06 0 (0%)

248.06

+2.2 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.62%
Inst Owner Change-2.08%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap17.87B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (32.63%)
Short Float %3.13%
Short Ratio2.33
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-6.91%
PT rev (3m)-5.85%
EPS NQ rev (1m)1.65%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)3.22%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)2.48%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 34.03
Fwd PE 30.62
P/S 5.81
P/FCF 38.1
P/OCF 23.67
P/B 5.63
P/tB 5.84
EV/EBITDA 21.54
EPS(TTM)7.29
EY2.94%
EPS(NY)8.1
Fwd EY3.27%
FCF(TTM)6.51
FCFY2.62%
OCF(TTM)10.48
OCFY4.22%
SpS42.68
BVpS44.1
TBVpS42.47
PEG (NY)3.05
PEG (5Y)3.8
Graham Number85.05
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.81
F-Score7
WACC10.78%
ROIC/WACC1.31
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 8 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.